prikaz prve stranice dokumenta Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama
  Download
PDF 728.71 KB
master's thesis
Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama
2021. urn:nbn:hr:152:934693
Lončar, Ana
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek

Cite this document

Lončar, A. (2021). Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama (Master's thesis). Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek. Retrieved from https://urn.nsk.hr/urn:nbn:hr:152:934693

Lončar, Ana. "Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2021. https://urn.nsk.hr/urn:nbn:hr:152:934693

Lončar, Ana. "Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2021. https://urn.nsk.hr/urn:nbn:hr:152:934693

Lončar, A. (2021). 'Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama', Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, accessed 20 November 2024, https://urn.nsk.hr/urn:nbn:hr:152:934693

Lončar A. Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama [Master's thesis]. Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek; 2021 [cited 2024 November 20] Available at: https://urn.nsk.hr/urn:nbn:hr:152:934693

A. Lončar, "Ekspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama", Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, 2021. Available at: https://urn.nsk.hr/urn:nbn:hr:152:934693

Please login to the repository to save this object to your list.
Metadata
TitleEkspresija liganda 1 programirane smrti stanice u bolesnika sa ne sitno staničnim karcinomom pluća: povezanost s kliničko-patološkim značajkama i molekularnim promjenama
Title (english)Programmed cell death ligand 1 expression in patienst with non small cell lung carcinoma association with clinical and pathological features and molecular alterations
AuthorAna Lončar
MentorKsenija Marjanović (mentor)
Committee memberIlijan Tomaš (predsjednik povjerenstva)
Committee memberJasmina Rajc (član povjerenstva)
Committee memberKsenija Marjanović (član povjerenstva)
GranterJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Osijek
Defense date and country2021-07-16, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract
CILJ: Cilj istraživanja je ispitati učestalost ekspresije PD-L1 u bolesnika s NSCLC te analizirati povezanost ekspresije PD-L1 s kliničko-patološkim karakteristikama bolesnika. USTROJ STUDIJE: Istraživanje je postavljeno kao presječno istraživanje. METODE: Istraživanjem su obuhvaćena 172 ispitanika (120 muškaraca i 52 žene) s NSCLC kod kojih je provedeno testiranje ekspresije PD-L1 na bioptičkom materijalu i staničnim blokovima, koja je određivana imunohistokemijskom metodom. REZULTATI: Median dobi ispitanika je 66 godina. Značajna razlika u umjerenoj i jakoj ekspresiji PD-L1 prema tipu tumora nije uočena. Iako jaku ekspresiju PD-L1 imaju nešto više žene, razlika u odnosu na spol nije uočena. Nešto su stariji ispitanici (od 70 i više godina) sa jakom ekspresijom PD-L1, no ta razlika nije uočena u odnosu na mlađe ispitanike. Također nije uočena razlika ekspresije PD-L1 u odnosu na dob i naviku pušenja te na spol i naviku pušenja. Umjerena i jaka ekspresija PD-L1 razlikovala se s obzirom na vrstu tumora i proširenost bolesti, a najučestaliji su adenokarcinomi u IVA stadiju. Iako nešto manji broj ispitanika s pozitivnim EGFR, ALK i ROS1 mutacijama ima umjerenu i jaku ekspresija PD-L1-a, razlike u raspodjeli nisu uočene. ZAKLJUČAK: Razlike u umjerenoj i jakoj ekspresiji PD-L1 prema tipu tumora, dobi, navici pušenja i spolu nisu uočene. Iako nešto manji broj ispitanika s pozitivnim EGFR, ALK i ROS1 mutacijama ima umjerenu i jaku ekspresija PD-L1-a, razlike u raspodjeli nisu uočene.Uočena je razlika u umjerenoj i jakoj ekspresije PD-L1 prema vrsti tumora i proširenosti bolesti, najučestaliji su adenokarcinomi u IVA stadiju.
Abstract (english)
OBJECTIVE: The aim of the study was to examine the frequency of PD-L1 expression in patients with NSCLC and to analyze the association of PD-L1 expression with clinical and pathological characteristics of patients. STUDY STRUCTURE: The survey was set up as a cross-sectional survey. METHODS: The study included 172 subjects (120 men and 52 women) with NSCLC in whom PD-L1 expression testing was performed on biopsy material and cell blocks, which was determined by immunohistochemical method. RESULTS: The median age of the respondents was 66 years. No significant difference in moderate and strong expression of PD-L1 by tumor type was observed. Although slightly more women have strong PD-L1 expression, no gender difference was observed. Slightly older subjects (aged 70 and over) had a strong PD-L1 expression, but this difference was not observed among younger subjects. There was also no difference in PD-L1 expression in relation to age and smoking habit and in gender and smoking habit. Moderate and strong PD-L1 expression varied according to tumor type and disease extent, with stage IV adenocarcinomas being the most common. Although a slightly smaller number of subjects with positive EGFR, ALK, and ROS1 mutations had moderate and strong expression of PD-L1, no differences in distribution were observed. CONCLUSION: No significant difference was found in moderate and strong expression of PD-L1 expression by tumor type, age, smoking habit, and gender were observed. Although a slightly smaller number of subjects with positive EGFR, ALK and ROS1 mutations have moderate and strong expression of PD-L1, no differences in the distribution were observed. stage IVA adenocarcinomas.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:152:934693
Study programmeTitle: University Graduate Studies
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-12-13 11:09:39